especialidad

Biblioteca Posters Congresos – 2025 – eadv – paris

biblioteca-posters-congresos-banner-sin-fondo

Evidencia reciente en congresos

A continuación, podrás acceder a los datos más recientes, presentados en los últimos congresos sobre el tratamiento de la psoriasis, la queratosis actínica leve en adultos e infecciones fúngicas leves o moderadas de las uñas:

2025
2024
08 banner 2025 eadv paris
Assessing the holistic value of tirbanibulin for treating actinic keratosis using multi-criteria decision analysis (MCDA) in three european countries
VISUALIZAR
Clearance of actinic keratosis with tirbanibulin: Comparing results from controlled trials with real-world/low interventional clinical studies
VISUALIZAR
Safety and tolerability of tirbanibulin for the treatment of actinic keratosis
VISUALIZAR
Relating patient-reported treatment satisfaction and clinical outcomes in post-registration studies of tirbanibulin for actinic keratosis
VISUALIZAR
LC-OCT with Al-based algorithm assessment of Tirbanibulin treatment for actinic keratosis
VISUALIZAR
Efficacy of 1% tirbanibulin in the treatment of pigmented actinic keratosis. A real-life ambispective study
VISUALIZAR
Real-world data on characteristics and management of patients with actinic keratosis: a cancer center experience
VISUALIZAR
Split-face case series of tirbanibulin 1% ointment versus photolyase-based repair cream in actinic keratosis
VISUALIZAR
09-titulo_10-2025-eadv-paris
VISUALIZAR
Highlighting the value of CAL/BDP pad cream in patients meeting the rule of 10s
VISUALIZAR
Incremental medication adherence results in incremental improvement in S-mPASI and worst itch scores among patients
VISUALIZAR
Relationship between patient reported outcomes (PROs) and clinician reported outcomes (ClinROs) and treatment adherence
VISUALIZAR
Impact of calcipotriol and betamethasone dipropionate cream with PAD technology (CAL/BPD PAD cream) on patient symptoms,
VISUALIZAR
Best responders to calcipotriol/betamethasone dipropionate (CAL/BDP) PAD cream
VISUALIZAR
Dermatología
.
Otras especialidades
Otros contenidos
©2025 Almirall
©2025 Almirall

EADV – 2025 – Paris

EADV – 2025 – Paris

09-popup_2-2025-eadv-paris

EADV – 2025 – Paris

09-popup_3-2025-eadv-paris

EADV – 2025 – Paris

09-popup_4-2025-eadv-paris

EADV – 2025 – Paris

09-popup_5-2025-eadv-paris

EADV – 2025 – Paris

09-popup_6-2025-eadv-paris

EADV – 2025 – Paris

09-popup_8-2025-eadv-paris

EADV – 2025 – Paris

09-popup_9-2025-eadv-paris

EADV – 2025 – Paris

09-popup_10-2025-eadv-paris

EADV – 2025 – Paris

09-popup_11-2025-eadv-paris

EADV – 2025 – Paris

popup - Incremental medication adherence results in incremental improvement in S-mPASI and worst itch scores among patients

EADV – 2025 – Paris

Popup - Relationship between patient reported outcomes (PROs) and clinician reported outcomes (ClinROs) and treatment adherence

EADV – 2025 – Paris

Popup - Impact of calcipotriol and betamethasone dipropionate cream with PAD technology (CAL/BPD PAD cream) on patient symptoms

EADV – 2025 – Paris

Popup - Best responders to calcipotriol/betamethasone dipropionate (CAL/BDP) PAD cream

EADV – 2025 – Paris

09-popup_7-2025-eadv-paris

La información proporcionada en este sitio web está destinada a profesionales de la salud capacitados para prescribir y suministrar medicamentos, así que requieren conocimiento científico específico y formación para interpretarla correctamente.

Soy profesional de la salud